| 10369217 |
Antigen-loaded chitosan nanoparticles for immunotherapy |
Andrea Hanefeld, Markus Weigandt, Percy KNOLLE, Matthias Schroeder, Regina Scherliess +4 more |
2019-08-06 |
$75,148,000 |
| 8816070 |
Triazole derivative as an HSP 90 inhibitor |
Hans-Michael Eggenweiler, Hans-Peter Buchstaller, Christian Sirrenberg |
2014-08-26 |
$59,520,000 |
| 8722903 |
Indazole derivatives for the treatment of HSP9O-induced diseases |
Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Christian Sirrenberg |
2014-05-13 |
$117,499,000 |
| 8618285 |
Triazole derivatives |
Hans-Michael Eggenweiler |
2013-12-31 |
$40,993,000 |
| 8119795 |
Triazole derivatives II |
Hans-Michael Eggenweiler, Hans-Peter Buchstaller, Christian Sirrenberg |
2012-02-21 |
$50,558,000 |
| 7989625 |
Thienopyridines |
Hans-Michael Eggenweiler |
2011-08-02 |
$62,368,000 |
| 7977343 |
Adenine derivatives |
Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Bertram Cezanne |
2011-07-12 |
$141,268,000 |
| 7947696 |
2-amino-4-phenylquinazoline derivatives and the use thereof as HSP90 modulators |
Hans-Michael Eggenweiler, Hans-Peter Buchstaller |
2011-05-24 |
$54,233,000 |
| 7943637 |
Thienopyridine derivatives and the use thereof as HSP90 modulators |
Hans-Michael Eggenweiler |
2011-05-17 |
$50,709,000 |
| 7932401 |
1,5-diphenylpyrazoles |
Hans-Michael Eggenweiler |
2011-04-26 |
$146,178,000 |
| 7906657 |
1,5-diphenylpyrazoles II as HSP90 inhibitors |
Hans-Michael Eggenweiler, Hans-Peter Buchstaller, Christian Sirrenberg |
2011-03-15 |
$44,210,000 |
| 7790723 |
Thiazole derivatives as phosphodiesterase IV inhibitors |
Hans-Michael Eggenweiler |
2010-09-07 |
$60,580,000 |
| 7563790 |
Pyridazine derivatives |
Hans-Michael Eggenweiler |
2009-07-21 |
$97,142,000 |
| 7544684 |
Hydrazono-malonitriles |
Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Thomas Ehring |
2009-06-09 |
$83,811,000 |
| 7498334 |
Pyrrolopyrimidines as phosphodiesterase VII inhibitors |
Hans-Michael Eggenweiler |
2009-03-03 |
$214,674,000 |
| 7491742 |
Imidazole derivatives as phosphodiesterase VII inhibitors |
Hans-Michael Eggenweiler, Rochus Jonas, Michael Gassen, Oliver Pöschke |
2009-02-17 |
$70,718,000 |
| 7485639 |
4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies |
Hans-Michael Eggenweiler, Norbert Beier, Joachim Leibrock, Pierre Schelling, Michael Gassen +1 more |
2009-02-03 |
$90,380,000 |
| 7470687 |
Aryl oximes |
Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling |
2008-12-30 |
$77,197,000 |
| 7312328 |
Benzoylpyridazines |
Hans-Michael Eggenweiler, Norbert Beier, Joachim Leibrock, Michael Gassen, Thomas Ehring |
2007-12-25 |
|
| 7141572 |
Hydrazono-malonitriles |
Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling, Thomas Ehring |
2006-11-28 |
$463,590,000 |
| 7135471 |
Aryl oximes |
Hans-Michael Eggenweiler, Norbert Beier, Pierre Schelling |
2006-11-14 |
$119,176,000 |
| 7129241 |
Pyridazine derivatives |
Hans-Michael Eggenweiler |
2006-10-31 |
$241,194,000 |
| 6884800 |
Imidazole compounds used as phosphodiesterase VII inhibitors |
Hans-Michael Eggenweiler, Rochus Jonas, Michael Gassen, Thomas Welge |
2005-04-26 |
$233,585,000 |
| 6737436 |
Pyrrole derivatives as phosphodiesterase VII inhibitors |
Hans-Michael Eggenweiler, Rochus Jonas, Michael Gassen, Thomas Welge |
2004-05-18 |
$166,009,000 |
| 6696446 |
Benzoylpyridazines, their preparation and use |
Rochus Jonas, Norbert Beier |
2004-02-24 |
$70,497,000 |
